Press release
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Monday, October 11, 2021, at 2:30 pm ET to announce its next clinical product candidates.\n\nGossamer management will present and discuss its forthcoming additions to its clinical product candidate pipeline. As part of the event, Gossamer Bio management will be available for questions.\n\nConference Call and Webcast\n\nGossamer will host a conference call and live audio webcast at 2:30 pm ET on Monday, October 11. The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following:\n\nConference ID: 4165598\nDomestic Dial-in Number: (833) 646-0603\nInternational Dial-in Number: (929) 517-9782\nLive Webcast: https://edge.media-server.com/mmc/p/4jha6kh9\n\nA replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com.\n\nAbout Gossamer Bio\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20211007005849/en/\n\nFor Investors and Media:\nBryan Giraudo, Chief Operating Officer & Chief Financial Officer\nGossamer Bio Investor Relations\[email protected]\n\nSource: Gossamer Bio, Inc.","length":4187,"tagName":"div"}]